What is the current market price of Napavir sodium (Sunlenca)?

Sunlenca (Sunlenca) is a new anti-HIV (AIDS) drug developed by Gilead Sciences. Its biggest feature is its long-acting mechanism of action. It is the first HIV-1 six-helical cap protein inhibitor drug and can exert inhibitory effects on multiple key links in the virus life cycle. Unlike traditional antiretroviral drugs, lenapavir sodium inhibits the replication and spread of the virus by blocking the assembly and function of the viral capsid. This innovative mechanism provides new hope for patients with previous drug resistance or long-term treatment failure, and especially shows good prospects for people infected with multidrug-resistant HIV-1.

Lenapavir sodium currently has two dosage forms: tablets and injections. The tablet specification is 300mg, which is generally used for oral guidance in the initial stage of treatment or maintenance treatment; the injection specification is 463.5mg/1.5ml×2 tubes, which is mainly used for long-term maintenance. In terms of price in overseas markets, a box of injections is about 100,000 yuan, while a package of 5 tablets is priced at about 50,000 yuan. This price is relatively high among global antiviral drugs, and there are currently no generic drugs on the market, so accessibility for domestic patients still faces certain challenges.

In China, both tablets and injections of lenapavir sodium have been approved for marketing, but have not yet been included in the medical insurance reimbursement list. This means that patients must pay for it themselves if they need to use it. Due to the short time the drug has been on the market and current distribution channels are limited, it is difficult to obtain it in actual clinical practice. However, with future market promotion, supply chain improvement, and the accumulation of more clinical application data, this situation is expected to gradually improve. Judging from international trends, long-acting antiviral drugs are gradually recognized as an important direction in HIV treatment, and lenapavir sodium is expected to become a representative drug in this field.

Reference materials:https://www.drugs.com/sunlenca.html